Crestline Management
Latest statistics and disclosures from Crestline Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DNLI, SANA, EGHT, and represent 100.00% of Crestline Management's stock portfolio.
- Reduced shares in these 1 stock: DNLI (-$7.7M).
- Crestline Management was a net seller of stock by $-7.7M.
- Crestline Management has $54M in assets under management (AUM), dropping by 15.58%.
- Central Index Key (CIK): 0001536054
Tip: Access up to 7 years of quarterly data
Positions held by Crestline Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Crestline Management
Crestline Management holds 3 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Denali Therapeutics (DNLI) | 91.9 | $49M | -13% | 1.9M | 25.72 |
|
| Sana Biotechnology (SANA) | 4.9 | $2.6M | 756k | 3.49 |
|
|
| 8x8 (EGHT) | 3.2 | $1.7M | 991k | 1.71 |
|
Past Filings by Crestline Management
SEC 13F filings are viewable for Crestline Management going back to 2011
- Crestline Management 2026 Q2 filed Aug. 14, 2026
- Crestline Management 2026 Q1 restated filed May 15, 2026
- Crestline Management 2025 Q4 filed Feb. 17, 2026
- Crestline Management 2025 Q3 filed Nov. 14, 2025
- Crestline Management 2025 Q2 filed Aug. 14, 2025
- Crestline Management 2025 Q1 filed May 15, 2025
- Crestline Management 2024 Q4 filed Feb. 14, 2025
- Crestline Management 2024 Q3 filed Nov. 13, 2024
- Crestline Management 2024 Q1 filed May 14, 2024
- Crestline Management 2023 Q4 filed Feb. 12, 2024
- Crestline Management 2023 Q3 filed Nov. 14, 2023
- Crestline Management 2023 Q2 filed Aug. 14, 2023
- Crestline Management 2023 Q1 filed May 15, 2023
- Crestline Management 2022 Q4 filed Feb. 13, 2023
- Crestline Management 2022 Q3 filed Nov. 14, 2022
- Crestline Management 2022 Q2 filed Aug. 12, 2022